search
Back to results

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

Primary Purpose

Nasal Congestion

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Diphenhydramine 50 mg
Diphenhydramine 25 mg
Pseudoephedrine 120 mg
Sponsored by
Johnson & Johnson Consumer and Personal Products Worldwide
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nasal Congestion focused on measuring Seasonal Allergic Rhinitis, nasal congestion

Eligibility Criteria

12 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • otherwise healthy males and females
  • 12 to 65 years of age
  • hypersensitivity to specific pollens for a minimum of 2 years prior to study start
  • appropriate SAR sign/symptoms scores

Exclusion Criteria:

  • pregnancy, lactation and contraception issues
  • contraindicated medications or therapies
  • evidence of clinical, dietary, lifestyle or psychiatric issues, which in the opinion of the investigator, could increase the risk to the subject or research staff, or interfere with the interpretation of study results

Sites / Locations

  • Benchmark Research - Austin
  • Allergy and Asthma Associates
  • Lovelace Scientific Resources
  • Allergy/Immunology Research Center of North Texas
  • Kerrville Research Associates
  • Central Texas Health Research
  • Benchmark Research - San Angelo
  • Sun Research Institute
  • Biogenics Research Institute
  • Diagnostics Research Group
  • Sylvana Research Associates
  • Allergy Asthma Research Institute

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

1

2

3

Arm Description

Diphenhydramine 50 mg

Diphenhydramine 25 mg

Pseudoephedrine 120 mg

Outcomes

Primary Outcome Measures

Change from baseline in the subject's mean reflective nasal congestion/stuffiness symptom score

Secondary Outcome Measures

Change from baseline in the subject's mean reflective Total Nasal Symptom (TNS) Score
Change from baseline in the subject's mean instantaneous TNS Score
Change from baseline in the subject's mean reflective Total SAR Symptom (TSS) Score
Change from baseline in the subject's mean instantaneous TSS Score
Change from baseline in the subject's mean reflective score for each of the seven remaining individual SAR symptoms, excluding nasal congestion/stuffiness
Change from baseline in the subject's mean instantaneous score for each of the eight individual SAR symptoms
Onset of action for diphenhydramine treatment for nasal congestion/stuffiness was determined by comparing the change from baseline in the subject's instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo
Onset of action for diphenhydramine treatment for allergic rhinitis symptoms was determined by comparing the change from baseline in the subject's instantaneous TNS scores for diphenhydramine versus placebo
Duration of action for diphenhydramine for treatment of nasal congestion/stuffiness was evaluated by comparing the change from baseline in the subject's mean instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo
Duration of action for diphenhydramine for treatment of allergic rhinitis symptoms was evaluated by comparing the change from baseline in the subject's mean instantaneous TNS scores for diphenhydramine versus placebo
Time to maximal effect was assessed by a by-day analysis of the primary efficacy endpoint and select secondary endpoints
Subject's global evaluation of response to treatment
Change from baseline in the Investigator's TNS score
Change from baseline in the Investigator's TSS score
Change from baseline for each of the eight individual Investigator's SAR symptoms
Investigator's global evaluation of the subject's response to treatment
Number and percentage of subjects experiencing adverse events
Change from baseline and potentially clinically important vital signs (systolic and diastolic blood pressure, pulse, and respiratory rate)
Occurrence of somnolence

Full Information

First Posted
March 20, 2008
Last Updated
August 19, 2011
Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
search

1. Study Identification

Unique Protocol Identification Number
NCT00648973
Brief Title
To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses
Official Title
Evaluation of Nasal Congestion Clinical Efficacy for Diphenhydramine 25 mg and Diphenhydramine 50 mg in Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo and Pseudoephedrine Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
May 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study was to determine if the drug worked to relieve nasal congestion experienced by people with seasonal allergies.
Detailed Description
Subjects who met the inclusion/exclusion criteria were enrolled into the placebo run-in phase of the study on Day -7 (prerandomization, Visit 1). Baseline symptom scores were established during this run-in phase. Subjects with moderate nasal congestion who took at least 80% of their study medication during the run-in phase were eligible for enrollment in the two-week double-blind phase of the study and were randomized on Day 1 (randomization, Visit 2). They were treated for two weeks with their assigned medication. The severity of signs/symptoms were evaluated by the subjects every morning and night and by the investigator at each visit on Day 7 and Day 14. In addition, the subject and investigator provided a global evaluation of response to treatment on Day 7 and Day 14. Safety was evaluated by adverse events reported during the study, vital signs, and the incidence of somnolence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasal Congestion
Keywords
Seasonal Allergic Rhinitis, nasal congestion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1021 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Diphenhydramine 50 mg
Arm Title
2
Arm Type
Experimental
Arm Description
Diphenhydramine 25 mg
Arm Title
3
Arm Type
Active Comparator
Arm Description
Pseudoephedrine 120 mg
Intervention Type
Drug
Intervention Name(s)
Diphenhydramine 50 mg
Other Intervention Name(s)
Active: Lot # 070PB6 Formula # W015990-0002
Intervention Description
Three times daily: two diphenhydramine 25 mg capsules Twice daily: one pseudoephedrine-matching placebo tablet
Intervention Type
Drug
Intervention Name(s)
Diphenhydramine 25 mg
Other Intervention Name(s)
Active: Lot # 070PB6 Formula # W015990-0002
Intervention Description
Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule Twice daily: one pseudoephedrine-matching placebo tablet
Intervention Type
Drug
Intervention Name(s)
Pseudoephedrine 120 mg
Other Intervention Name(s)
Active: Lot # INT-06-115 Formula # W015721-0004
Intervention Description
Three times daily: two diphenhydramine-matching placebo capsules Twice daily: one pseudoephedrine 120 mg tablet
Primary Outcome Measure Information:
Title
Change from baseline in the subject's mean reflective nasal congestion/stuffiness symptom score
Time Frame
every 12-hours over the 14-day treatment period
Secondary Outcome Measure Information:
Title
Change from baseline in the subject's mean reflective Total Nasal Symptom (TNS) Score
Time Frame
14 Days
Title
Change from baseline in the subject's mean instantaneous TNS Score
Time Frame
14 Days
Title
Change from baseline in the subject's mean reflective Total SAR Symptom (TSS) Score
Time Frame
14 Days
Title
Change from baseline in the subject's mean instantaneous TSS Score
Time Frame
14 Days
Title
Change from baseline in the subject's mean reflective score for each of the seven remaining individual SAR symptoms, excluding nasal congestion/stuffiness
Time Frame
14 Days
Title
Change from baseline in the subject's mean instantaneous score for each of the eight individual SAR symptoms
Time Frame
14 Days
Title
Onset of action for diphenhydramine treatment for nasal congestion/stuffiness was determined by comparing the change from baseline in the subject's instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo
Time Frame
taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose.
Title
Onset of action for diphenhydramine treatment for allergic rhinitis symptoms was determined by comparing the change from baseline in the subject's instantaneous TNS scores for diphenhydramine versus placebo
Time Frame
taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose
Title
Duration of action for diphenhydramine for treatment of nasal congestion/stuffiness was evaluated by comparing the change from baseline in the subject's mean instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo
Time Frame
taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose)
Title
Duration of action for diphenhydramine for treatment of allergic rhinitis symptoms was evaluated by comparing the change from baseline in the subject's mean instantaneous TNS scores for diphenhydramine versus placebo
Time Frame
taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose)
Title
Time to maximal effect was assessed by a by-day analysis of the primary efficacy endpoint and select secondary endpoints
Time Frame
14 Days
Title
Subject's global evaluation of response to treatment
Time Frame
at Visits 3 and 4, analyzed separately at each visit
Title
Change from baseline in the Investigator's TNS score
Time Frame
at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1
Title
Change from baseline in the Investigator's TSS score
Time Frame
at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1
Title
Change from baseline for each of the eight individual Investigator's SAR symptoms
Time Frame
at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1
Title
Investigator's global evaluation of the subject's response to treatment
Time Frame
at Visits 3 and 4, analyzed separately for each visit
Title
Number and percentage of subjects experiencing adverse events
Time Frame
Duration of study
Title
Change from baseline and potentially clinically important vital signs (systolic and diastolic blood pressure, pulse, and respiratory rate)
Time Frame
Duration of study
Title
Occurrence of somnolence
Time Frame
Overall and weekly

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: otherwise healthy males and females 12 to 65 years of age hypersensitivity to specific pollens for a minimum of 2 years prior to study start appropriate SAR sign/symptoms scores Exclusion Criteria: pregnancy, lactation and contraception issues contraindicated medications or therapies evidence of clinical, dietary, lifestyle or psychiatric issues, which in the opinion of the investigator, could increase the risk to the subject or research staff, or interfere with the interpretation of study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melissa Israel, BS
Organizational Affiliation
McNeil Consumer Healthcare Division of Mc-Neil-PPC, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Benchmark Research - Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Allergy and Asthma Associates
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
Lovelace Scientific Resources
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
Allergy/Immunology Research Center of North Texas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Kerrville Research Associates
City
Kerrville
State/Province
Texas
ZIP/Postal Code
78028
Country
United States
Facility Name
Central Texas Health Research
City
New Braunfels
State/Province
Texas
ZIP/Postal Code
78130
Country
United States
Facility Name
Benchmark Research - San Angelo
City
San Angelo
State/Province
Texas
ZIP/Postal Code
76904
Country
United States
Facility Name
Sun Research Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78205
Country
United States
Facility Name
Biogenics Research Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Diagnostics Research Group
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Sylvana Research Associates
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Allergy Asthma Research Institute
City
Waco
State/Province
Texas
ZIP/Postal Code
76712
Country
United States

12. IPD Sharing Statement

Learn more about this trial

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

We'll reach out to this number within 24 hrs